Immuno-oncology & Precision Medicine
Oncology
ServiceActive
Key Facts
About ImmuneSpec
Founded in 2017 and based in Leuven, Belgium, ImmuneSpec is a specialized service provider in the immunopeptidomics space. The company leverages a proprietary, high-sensitivity platform to identify peptides presented by MHC molecules, offering crucial insights for biotherapeutic developers in immunogenicity testing, vaccine design, and cancer immunotherapy target validation. As a private, likely pre-revenue or early-revenue company, ImmuneSpec operates on a B2B service model, partnering with pharmaceutical and biotech clients to de-risk and accelerate their R&D pipelines through precise, data-driven epitope mapping.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |